PARP INHIBITOR MARKET ANALYSIS

PARP Inhibitor Market, By Drug Type (Niraparib, Olaparib, Rucaparib, Talazoparib, Veliparib, Others), By Application (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In June 2024,Pfizer,Pharmaceutical company has announced that the FDA approved TALZENNA (talazoparib), a PARP inhibitor, in combination with XTANDI (enzalutamide), for treating adults with metastatic castration-resistant prostate cancer (mCRPC) who have specific gene mutations related to homologous recombination repair (HRR).
In August 2023, Janssen, part of Johnson & Johnson pharmaceutical company, has received USFDA approval for AKEEGA, a novel tablet combining niraparib (a PARP inhibitor) with abiraterone acetate, alongside prednisone. It is the first and only dual-action treatment for adult patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test.
In June 2023, AstraZeneca and Merck (known as MSD in certain regions) have announced FDA approval for LYNPARZA in combination with abiraterone and prednisone/prednisolone for treating adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Selection of patients for this therapy should be based on an FDA-approved companion diagnostic for LYNPARZA.
In April 2020, GlaxoSmithKline (GSK) announced FDA approval for Zejula (niraparib) as a standalone maintenance treatment for women with advanced ovarian, fallopian tube, or peritoneal cancer who have responded to initial platinum-based chemotherapy, regardless of biomarker status. This expands treatment access beyond the previous 20% restricted to those with BRCA mutations.